Staff Members - Benha University
Serum BLyS and APRIL as possible indicators of disease activity in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis
The Egyptian Rheumatologist • 2014
Publication Information
Authors
Gehan Gamal Elolemy a,*, Eman Abdelalem Baraka a, Soha Abdelhady Gendy b,Eman Ramadan Abdelgwad c, Abeer Ahmed Aboelazm
Keywords
Not Available
Journal
The Egyptian Rheumatologist
Publisher
Elsevier
Volume
36
Issue
Not Available
Pages
93-99
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Abstract Aim of the work: To assess serum levels of B lymphocyte stimulator (BLyS) and a proliferation-
inducing ligand (APRIL) to determine their correlations with disease activity in pediatric
systemic lupus erythematosus (pSLE) and juvenile idiopathic arthritis (JIA) patients.
Patients and methods: Twenty-nine pSLE patients and 33 JIA patients were recruited. SLE disease
activity was assessed using the systemic lupus erythematosus disease activity index (SLEDAI),
while the juvenile arthritis 27 joint disease activity score (JADAS-27) was calculated for JIA
patients. Serum samples were assayed for BLyS and APRIL by the enzyme linked immunosorbent
assay (ELISA).
Results: Serum BLyS and APRIL were elevated in both pSLE and JIA patients compared to
controls. Serum BLyS levels correlated with both SLE and JIA disease activity (p=0.042,
p= 0.019, respectively) whereas serum APRIL levels correlated positively with JADAS-27 and
inversely with SLEDAI (p= 0.001, p= 0.02, respectively). Elevated serum BLyS and APRIL were
significantly associated with a lower incidence of nephritis (p= 0.043, p= 0.016, respectively),
while elevated serum APRIL significantly associated with negative anti-dsDNA in pSLE patients
(p= 0.017). In JIA patients, both serum BLyS and APRIL were significantly associated with the
inducing ligand (APRIL) to determine their correlations with disease activity in pediatric
systemic lupus erythematosus (pSLE) and juvenile idiopathic arthritis (JIA) patients.
Patients and methods: Twenty-nine pSLE patients and 33 JIA patients were recruited. SLE disease
activity was assessed using the systemic lupus erythematosus disease activity index (SLEDAI),
while the juvenile arthritis 27 joint disease activity score (JADAS-27) was calculated for JIA
patients. Serum samples were assayed for BLyS and APRIL by the enzyme linked immunosorbent
assay (ELISA).
Results: Serum BLyS and APRIL were elevated in both pSLE and JIA patients compared to
controls. Serum BLyS levels correlated with both SLE and JIA disease activity (p=0.042,
p= 0.019, respectively) whereas serum APRIL levels correlated positively with JADAS-27 and
inversely with SLEDAI (p= 0.001, p= 0.02, respectively). Elevated serum BLyS and APRIL were
significantly associated with a lower incidence of nephritis (p= 0.043, p= 0.016, respectively),
while elevated serum APRIL significantly associated with negative anti-dsDNA in pSLE patients
(p= 0.017). In JIA patients, both serum BLyS and APRIL were significantly associated with the